The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

Boccardo F;Viale G;Wang Y;Rubino C;Bruzzi P;Del Mastro L;Sertoli Mr;Rubagotti A;
2017

Abstract

The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment.
File in questo prodotto:
File Dimensione Formato  
emss-75008.pdf

accesso aperto

Tipologia: Documento in versione editoriale
Dimensione 1.12 MB
Formato Adobe PDF
1.12 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/881777
Citazioni
  • ???jsp.display-item.citation.pmc??? 398
  • Scopus 698
  • ???jsp.display-item.citation.isi??? 675
social impact